Economic TimesPipeline Setback at Abbott – Analyst BlogNASDAQOther late-stage candidates at Abbott Labs includes levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson's disease and daclizumab for the treatment of relapsing-remitting multi…
Pipeline Setback at AbbottZacks.comOther late-stage candidates at Abbott Labs includes levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson's disease and daclizumab for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbo…
SCLEROSI MULTIPLA: VICINI AD UNA SVOLTALiberoQuotidiano.itDAC HYP (daclizumab high yeld process): è una terapia sottocutanea mensile, attualmente al centro di studi di fase 3, per il trattamento della SMRR (sclerosi multipla recidivante-remittente). E…
Through 2021, The Number of Disease-Modifying Therapies Approved for The …MarketWatch (press release)However, Decision Resources expects outstanding safety concerns will constrain the adoption of these potentially high-risk/high-reward therapies by a…
Economic TimesEPS Beat for Abbott, Sales Miss – Analyst BlogNASDAQAbbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Results are expected in…
Abbott Laboratories Management Discusses Q3 2012 Results – Earnings Call …Seeking AlphaDaclizumab is our next-generation biologic in development with Biogen for relapsing-remitting multiple sclerosis. Results from 1 of the 2 pivotal trials demonstrat…
Pancreas/Kidney Graft Improves Survival for Type 1 PatientsClinical Endocrinology News Digital NetworkAfter that time, patients receiving a single kidney began to receive basiliximab and the dual-transplant patients got thymoglobulin. The overall 15-ye…
Safety Issue Puts Daclizumab in Doubt for MSMedPage TodayLYON, France — Daclizumab, a biologic drug targeting the interleukin-2 pathway, showed sustained efficacy in the second year of a phase II trial in multiple sclerosis, but serious autoimmune iss…
Biogen sees bright future in MS combo therapiesPharma TimesHe also highlighted the progress being made on a pegylated version of its blockbuster Avonex (interferon beta-1a) and Abbott-partnered daclizumab,. Asked which of the current pipeline compounds…
BUSINESS WIRE: Biogen Idecs Engagement für multiple Sklerose auf 28 …Vereinigte WirtschaftsdiensteDaclizumab High-Yield Process (DAC HYP) ist eine subkutan verabreichte Formulierung von Daclizumab im fortgeschrittenen Stadium der klinischen Entwickl…